| Industry | 批发和零售业 | ||||||||||||||||||||||||
| Company Introduction | 南京医药股份有限公司成立于1951年，1996年在上海证券交易所上市，是中国医药流通行业较早上市公司，现已发展成为跨地区、网络型的集团化企业。2014年末，公司引入境外战略投资者，积极探索混合所有制改革。公司现注册资本约13亿元，国资控股股东为中国500强企业南京新工投资集团有限责任公司（持股44.13%）；外资股东为世界500强WalgreensBootsAlliance（沃博联）下属子公司AllianceHealthcareAsiaPacificLimited（持股11.03%）。 公司立足于大健康产业发展，以医药批发及医药零售为主营业务，是中国医药流通行业区域性龙头企业。公司现有90余家分子企业，市场网络覆盖江苏、安徽、湖北、福建等地及西南区域的昆明市（在江苏、安徽、湖北、福建四省市场占有率位居前列），业务覆盖近70个城市，在区域市场积累了丰富的医药商业运作经验、资源和品牌知名度。公司年营业收入超535亿元，居2023年国内医药流通行业规模排名第6位，居2024年《财富》中国500强第318位。 公司曾荣获“全国医药流通创新示范企业”称号，是第一批“全国供应链创新与应用示范企业”；荣获“江苏省五一劳动奖状”“南京市‘推动高质量发展，争当示范引领’先进集体”；是南京市新医药与生命健康产业链链主企业之一，以及南京市流通领域医药现代供应链体系项目示范企业，获评南京市市级综合型总部企业。 公司将以习近平新时代中国特色社会主义思想为指导，全面贯彻新发展理念，加快构建新发展格局，围绕公司“十四五”战略规划和“价值发现、批零协同、药械相长、适度延伸、数字赋能”发展思路，踔厉奋发、勇毅前行，努力成为大健康产业领先、可信赖的健康产品和服务提供商，为社会发展和公众健康作出新的更大贡献！ | ||||||||||||||||||||||||
| Main Business | 经营药品、医疗器械、化学试剂、玻璃仪器四大类商品以及医药产品的研制、开发、生产、销售 | ||||||||||||||||||||||||
| Legal Representative | 周建军 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 王冠 | ||||||||||||||||||||||||
| Solicitors | 北京市竞天公诚律师事务所 | ||||||||||||||||||||||||
| Auditors | 毕马威华振会计师事务所(特殊普通合伙) | ||||||||||||||||||||||||
| Tel No | 025-84552680;025-84552653 | ||||||||||||||||||||||||
| Fax No | 025-84552680;025-84552653 | ||||||||||||||||||||||||
| Website | www.njyy.com | ||||||||||||||||||||||||
| 600713@njyy.com；liwenjun1@njyy.com；wangguan@njyy.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 01/07/1996 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.438 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.170 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 5.216 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 6.435B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |